Gastroenteropancreatic neuroendocrine neoplasm

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:100092
Who is this for?
Show terms as
2FDA treatments4Active trials32Specialists8Treatment centers1Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

GEP-NEN
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Oct 2025Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Emory University — PHASE1

TrialRECRUITING
Aug 2025Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — PHASE2, PHASE3

TrialRECRUITING
Aug 2025Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan — PHASE1, PHASE2

TrialENROLLING BY INVITATION
May 2025Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Novartis Pharmaceuticals — PHASE3

TrialRECRUITING
May 2025Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Mainline Biosciences (Shanghai) Co., Ltd — PHASE1, PHASE2

TrialRECRUITING
Dec 2024Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

University Hospital, Strasbourg, France

TrialRECRUITING
May 2024Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center — PHASE4

TrialRECRUITING
Apr 2024

Lutathera: FDA approved

treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors

FDAcompleted
Mar 2024Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Assistance Publique - Hôpitaux de Paris — NA

TrialRECRUITING
Feb 2024Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Jiangsu HengRui Medicine Co., Ltd. — PHASE3

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Somatuline Depot

Lanreotide· IPSEN, Inc.
the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-fre…

the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival

View Details →FDA Label ↗

Lutathera

lutetium Lu 177 dotatate· Advanced Accelerator ApplicationsOrphan Drug
treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroen…

treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors

View Details →FDA Label ↗Patient Assistance ↗

Clinical Trials

4 recruitingView all trials with filters →
Phase 12 trials
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
Phase 1
Active
PI: Lowell B Anthony (Ohio State University Comprehensive Cancer Center ) · Sites: Duarte, California; Miami, Florida +3 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Phase 1
Active
PI: Amr Mohamed, MD (University Hospitals Cleveland Medical Center, Cas) · Sites: Cleveland, Ohio · Age: 18–80 yrs
View on ClinicalTrials.gov ↗I'm interested →
N/A1 trial
Surgical Intervention and the NETest
N/A
Active
· Sites: Milan · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other1 trial
Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
Actively Recruiting
PI: Gabriele Capurso, PhD (IRCCS Ospedale San Raffaele) · Sites: Milan · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 32View all specialists →
UD
Urielle Desalbres
Specialist
PI on 21 active trials1 Gastroenteropancreatic neuroendocrine neoplasm publication
ND
Nageshwara V Dasari
HOUSTON, TX
Specialist
PI on 2 active trials
JX
Jianming Xu
Specialist
PI on 2 active trials
JM
Jonathan Strosberg, M.D.
TAMPA, FL
Specialist
PI on 6 active trials
AM
Amr Mohamed, MD
Specialist
PI on 1 active trial
UM
Ur Metser, MD
Specialist
PI on 3 active trials
GT
Ghoufrane TLILI
Specialist
PI on 1 active trial
AM
Alain Hendlisz, MD
Specialist
PI on 1 active trial
AM
Amélie Deleporte, MD
Specialist
PI on 1 active trial
DM
Damian Wild, Prof. Dr. med.
Specialist
PI on 1 active trial
PM
Pretesh Patel, MD
DURHAM, NC
Specialist
PI on 1 active trial
BM
Brendan C Visser, MD
STANFORD, CA
Specialist
PI on 1 active trial
HM
Halfdan Sorbye, MD
Specialist
PI on 1 active trial
BM
Baek-Yeol Ryoo, MD
Specialist
PI on 1 active trial
MP
Michael O'Rorke, PhD
Specialist
PI on 1 active trial
GS
Giovanni Schinzari
Specialist
PI on 1 active trial
MP
María Isabel del Olmo García, M.D. Ph.D.
Specialist
PI on 1 active trial
MP
María Argente Pla, M.D. Ph.D.
Specialist
PI on 1 active trial
CM
Catherine Ansquer, MD
Specialist
PI on 1 active trial
DM
Diane Reidy-Lagunes, MD
NEW YORK, NY
Specialist
PI on 1 active trial
SK
Stefan Kasper
SAN FRANCISCO, CA
Specialist
2 Gastroenteropancreatic neuroendocrine neoplasm publications
RG
Rocío García-Carbonero
Specialist
PI on 1 active trial
AF
Andrea Frilling
Specialist
PI on 1 active trial
LA
Lowell B Anthony
LEXINGTON, KY
Specialist
PI on 1 active trial
SH
Susumu Hijioka
Specialist
2 Gastroenteropancreatic neuroendocrine neoplasm publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Lutathera(lutetium Lu 177 dotatate)— Advanced Accelerator Applications

Travel Grants

No travel grants are currently matched to Gastroenteropancreatic neuroendocrine neoplasm.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Gastroenteropancreatic neuroendocrine neoplasmForum →

No community posts yet. Be the first to share your experience with Gastroenteropancreatic neuroendocrine neoplasm.

Start the conversation →

Latest news about Gastroenteropancreatic neuroendocrine neoplasm

Disease timeline:

New recruiting trial: A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

New recruiting trial: Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

A new clinical trial is recruiting patients for Gastroenteropancreatic neuroendocrine neoplasm

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Gastroenteropancreatic neuroendocrine neoplasm

Are there clinical trials for Gastroenteropancreatic neuroendocrine neoplasm?

Yes — 4 recruiting clinical trials are currently listed for Gastroenteropancreatic neuroendocrine neoplasm on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Gastroenteropancreatic neuroendocrine neoplasm?

25 specialists and care centers treating Gastroenteropancreatic neuroendocrine neoplasm are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Gastroenteropancreatic neuroendocrine neoplasm?

1 patient support program are currently tracked on UniteRare for Gastroenteropancreatic neuroendocrine neoplasm. See the treatments and support programs sections for copay assistance, eligibility, and contact details.